ISSN: 2584-0355
DOI: doi.org/10.51219/MCCRJ/Supriya-Peshin/117

URF PUBLISHERS
connect with research world

Medical & Clinical Case Reports Journal

https://urfpublishers.com/journal/case-reports

Vol: 2 & Iss: 3

Review

Advancements in Cancer Immunotherapy: A Comprehensive Review of Immune Checkpoint Inhibitors with a Focus on Pembrolizumab and Emerging Strategies

Supriya Peshin[1]*, MD, Shivani Modi[1], MD and Shagun Singh[3], MD

[1]Norton Community Hospital, Virginia, USA

[2]Jefferson Einstein Healthcare Network, Norristown, Philadelphia, USA

[3]Banner University Medical Center, Tucson, Arizona, USA

Citation: Peshin S, Modi S, Singh S. Advancements in Cancer Immunotherapy: A Comprehensive Review of Immune Checkpoint Inhibitors with a Focus on Pembrolizumab and Emerging Strategies. *Medi Clin Case Rep J* 2024;2(3):430-434. DOI: doi.org/10.51219/MCCRJ/Supriya-Peshin/117

Received: 01 August, 2024; **Accepted:** 02 August, 2024; **Published:** 05 August, 2024

***Corresponding author:** Dr. Supriya Peshin, MD, Norton Community Hospital, Virginia, USA

ABSTRACT

The introduction of immune checkpoint inhibitors (ICIs) has marked a significant breakthrough in oncology, fundamentally altering cancer treatment paradigms. This review examines the transformative impact of ICIs, including PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab), all of which have received FDA approval for various malignancies. These agents enhance survival outcomes by reactivating the immune system to target cancer cells. Focused particularly on Pembrolizumab, a prominent PD-1 inhibitor, the review details its mechanism of action, which involves blocking the PD-1/PD-L1 interaction to restore T-cell activity against tumors. Pembrolizumab's efficacy is highlighted through clinical trials in non-small cell lung cancer, melanoma, and other cancers, demonstrating its broad-spectrum efficacy and safety profile. Predictors of response, such as PD-L1 expression and tumor mutational burden, are discussed alongside the associated immune-related adverse events (irAEs) and their management. Future directions include refining patient selection criteria, improving irAE management, and leveraging computational algorithms for personalized therapy. Emerging research on fecal microbiota transplantation (FMT) suggests the potential for enhancing ICI efficacy and managing side effects. Continued innovation and research are crucial for optimizing ICI therapy and addressing existing challenges to fully realize their potential in cancer treatment.

Keywords: Immune checkpoint inhibitors; Fecal microbiota transplantation; Autoimmunity

Introduction

The advent of immune checkpoint inhibitors (ICIs) has significantly transformed the treatment landscape of various cancers. This class of drugs, comprising PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab), has been approved by the US Food and Drug Administration (FDA) for several types of cancer. ICIs have demonstrated remarkable efficacy in improving survival outcomes for patients with advanced and metastatic cancers by stimulating the immune system to recognize and destroy cancer cells. This review explores the mechanisms of action, clinical applications, predictors of response, side effects, management strategies, and future directions of ICIs, with a particular focus on Pembrolizumab, a notable PD-1 inhibitor[1].

Mechanism of Action

Immune Checkpoints and Their Role

Immune checkpoints are essential components of the immune system that help maintain self-tolerance and prevent autoimmunity. These checkpoints are regulatory pathways that modulate the immune response to ensure it is appropriately targeted and not overly aggressive. They primarily function through interactions between immune checkpoint receptors on T-cells and their corresponding ligands on antigen-presenting cells or tumor cells.

Two key immune checkpoint pathways relevant to cancer therapy are the PD-1/PD-L1 and CTLA-4 pathways:

1. PD-1/PD-L1 Pathway:

- **PD-1 (Programmed Cell Death Protein 1)**: A receptor expressed on the surface of T-cells.
- **PD-L1 (Programmed Death-Ligand 1)**: A ligand that binds to PD-1, expressed on tumor cells and antigen-presenting cells.
- **PD-L2 (Programmed Death-Ligand 2)**: Another ligand for PD-1, found on some antigen-presenting cells.

Under normal circumstances, the interaction between PD-1 and PD-L1/Pd-L2 acts as a brake on T-cell activity, reducing immune responses and promoting tolerance. This mechanism helps prevent autoimmunity by inhibiting excessive immune reactions against self-antigens.

2. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4):

- **CTLA-4**: A receptor expressed on T-cells that competes with the costimulatory receptor CD28 for binding to B7 molecules (CD80/CD86) on antigen-presenting cells.
- **CD80/CD86**: Ligands on antigen-presenting cells that provide necessary signals for T-cell activation.

CTLA-4 engagement with CD80/CD86 inhibits T-cell activation and promotes T-cell exhaustion, contributing to immune evasion by tumors[2].

Mechanism of Action of Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody that specifically targets PD-1. The detailed mechanism of action is as follows:

1. Binding to PD-1:

Pembrolizumab binds with high affinity to PD-1 receptors on T-cells, thereby blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 **(Figure 1)**.

This inhibition prevents the PD-1/PD-L1 and PD-1/PD-L2 interactions, which are crucial for downregulating T-cell responses.

2. Reactivation of T-Cells:

By blocking PD-1, Pembrolizumab removes the inhibitory signals that would otherwise dampen T-cell activity.

This reactivation of T-cells enhances their ability to recognize and attack tumor cells, effectively boosting the anti-tumor immune response.

3. Lack of Direct Cytotoxic Effects:

Unlike cytotoxic antibodies that directly kill target cells through mechanisms like complement activation or engagement of Fc receptors, Pembrolizumab does not induce direct cell death.

It operates through immunomodulation rather than cytotoxicity, altering the immune environment to enhance T-cell-mediated tumor destruction.

4. Effective Inhibitory Concentration:

The 50% effective inhibitory concentration (IC50) of Pembrolizumab in T-cell activation assays, which measures its potency, ranges from 0.1 to 0.3 nM. This indicates its strong efficacy in blocking the PD-1 pathway and reactivating T-cells[2]

In summary, Pembrolizumab functions by blocking the PD-1 receptor on T-cells, thereby disrupting the inhibitory signals that tumors use to evade immune surveillance. This action restores and enhances T-cell activity against cancer cells, making it a powerful tool in cancer immunotherapy.



Figure 1: Mechanism of action of pembrolizumab.

Clinical Applications

Non-Small Cell Lung Cancer (NSCLC)

Survival Advantage and Clinical Trials: Pembrolizumab has significantly altered the treatment landscape for advanced NSCLC, particularly in patients with high PD-L1 expression. The KEYNOTE-024 trial, a landmark study, evaluated Pembrolizumab as a first-line treatment for patients with NSCLC and a PD-L1 tumor proportion score (TPS) of 50% or greater.

KEYNOTE-024 Trial Findings: The trial demonstrated that Pembrolizumab provided a substantial survival benefit compared to platinum-based chemotherapy. Patients treated with Pembrolizumab had a median overall survival (OS) of 20.0 months versus 12.2 months for those receiving chemotherapy. Furthermore, Pembrolizumab was associated with a higher progression-free survival (PFS) rate, highlighting its effectiveness as a first-line therapy[3].

Adverse Events: The trial also revealed a favorable safety profile for Pembrolizumab compared to chemotherapy. Pembrolizumab resulted in fewer severe treatment-related adverse events (31.2%) compared to chemotherapy (53.3%), underscoring its relative safety advantage[3].

Melanoma

The KEYNOTE-001 trial assessed Pembrolizumab, a PD-1 inhibitor, in advanced melanoma patients. It demonstrated:

- **Sustained Effectiveness:** Pembrolizumab provided durable tumor responses over five years, with high objective response rates in both treatment-naive and previously treated patients.
- **Safety Profile:** The drug maintained a favorable safety profile with manageable immune-related adverse events and comparable or improved quality of life outcomes.
- **Clinical Implications:** Effective as both a first-line and subsequent treatment, Pembrolizumab showed long-term benefit and flexibility in managing advanced melanoma[4]

Real-World Data: Real-world studies further supported the trial findings:

- **Durability of Response**: Pembrolizumab offered long-lasting responses similar to trial results, with benefits extending across various patient populations.
- **Clinical Outcomes**: Enhanced overall survival and improved quality of life in clinical practice were reported.
- **Safety and Tolerability**: Consistent with trial data, the safety profile was favorable, confirming Pembrolizumab's role as a long-term therapeutic option[5]

Overall, both the KEYNOTE-001 trial and real-world evidence affirm Pembrolizumab as a highly effective and safe treatment for advanced melanoma.

Pembrolizumab, a leading PD-1 inhibitor, has proven highly effective across various cancers beyond melanoma and non-small cell lung cancer. In head and neck squamous cell carcinoma (HNSCC), Pembrolizumab has shown significant efficacy in both recurrent and metastatic cases, as demonstrated by the KEYNOTE-012 and KEYNOTE-040 trials, offering notable survival benefits, especially for patients with high PD-L1 expression. For urothelial carcinoma, Pembrolizumab has exhibited strong performance in both first-line and second-line treatments, with trials such as KEYNOTE-052 and KEYNOTE-045 highlighting its impact on overall survival and progression-free survival. Similarly, in gastric cancer, Pembrolizumab has shown promising results in advanced stages, with trials like KEYNOTE-059 and KEYNOTE-061 confirming its durable responses and safety profile **(Tab1e 1)**. Overall, Pembrolizumab's versatility across these diverse cancers, coupled with its manageable safety profile, underscores its significant role in modern cancer immunotherapy[6].

Table 1: Clinical Applications of Pembrolizumab.

Cancer Type	Trial/Study	Outcome	Reference
Non-Small Cell Lung Cancer (NSCLC)	KEYNOTE-024	Improved survival compared to chemotherapy; fewer severe adverse events.	Reck et al., 2016
Melanoma	KEYNOTE-001	Sustained tumor response and safety over five years.	Larkin et al., 2015
Head and Neck Squamous Cell Carcinoma	-	Demonstrated efficacy and safety.	-
Urothelial Carcinoma	-	Effective across various stages; ongoing trials.	-
Gastric Cancer	-	Broad-spectrum efficacy; ongoing research on survival benefits.	-

Predictors of Response

Several biomarkers can predict the response to Pembrolizumab. Tumor cell PD-L1 expression is a well-established predictor of response, with higher expression levels correlating with better outcomes[7]. Tumors with high mutational burdens and subsequent formation of tumor-associated neo-antigens tend to respond more favorably to Pembrolizumab[8]. Research into gut microbiota suggests that a baseline microbiota rich in Firmicutes and Faecalibacterium may be associated with improved clinical responses and increased incidence of colitis with Ipilimumab treatment[9].

Side Effects Profile

While immune checkpoint inhibitors (ICIs) like Pembrolizumab generally exhibit a favorable safety profile compared to traditional chemotherapy, they are not without their own set of adverse effects. Pembrolizumab is associated with a variety of immune-related adverse events (irAEs) due to its mechanism of enhancing immune system activity against cancer cells.

Common irAEs include dermatologic reactions such as lichenoid reactions and eczema, gastrointestinal issues like colitis and hepatitis, and endocrine disorders, including thyroiditis and adrenalitis. A meta-analysis comparing Pembrolizumab with chemotherapy found no significant difference in the risk of fatal adverse events (FAEs) between the two treatments. However, certain adverse events, such as infections and pneumonitis, are particularly notable due to their potential severity[10,11].

Severe hematologic adverse effects, although relatively rare, have also been documented with Pembrolizumab. These include autoimmune anemia, such as autoimmune hemolytic anemia (AIHA), and immune thrombocytopenia, which can lead to significant health concerns. Case reports have highlighted instances of pancytopenia, a condition characterized by reduced levels of red blood cells, white blood cells, and platelets, associated with Pembrolizumab treatment[12,13]. Furthermore, clinical trials have frequently observed adverse events like neutropenia and anemia, which require careful monitoring and management[14,15]. Thus, while Pembrolizumab offers substantial therapeutic benefits, its associated adverse effects underscore the importance of ongoing vigilance and proactive management strategies to ensure patient safety and optimize treatment outcomes **(Table 2)**.

Table 2: Side Effects Profile of Pembrolizumab.

Adverse Event	Description	Incidence	Reference
Skin Reactions	Includes lichenoid reactions, eczema	Common	Haane&Carbonnel,2018
Gastrointestinal Issues	Includes diarrhea, colitis.	Common	-
Endocrine Disorders	Includes thyroiditis, adrenalitis	Common	-
Hematologic Adverse Effects	Autoimmune anemia, immune thrombocytopenia.	**Rare**	Wang & Shi, 2020; Valpione &Kotecha, 2020
Infections and Pneumonitis	Notable for severe cases.	Notable	Dougan & Shulman, 2020

Management of Side Effects

The management of ICIs involves early recognition and prompt intervention of immune-related adverse events (irAEs). Standard management strategies include corticosteroids and other immunosuppressive agents for severe irAEs. Hematologic complications may require specific treatments such as transfusions, steroids, or immunoglobulins, depending on the severity and type of adverse event[16].

Early Recognition and Monitoring

- **Early Detection:** Early recognition of irAEs is crucial for effective management. Regular monitoring, including clinical assessments, laboratory tests, and imaging studies, aids in identifying irAEs at an early stage. Patients should be educated about the potential side effects of ICIs and encouraged to report any new symptoms promptly.
- **Tapering and Discontinuation:** Once the irAE is under control, corticosteroids should be gradually tapered to avoid rebound inflammation. The tapering schedule depends on the initial dose and duration of corticosteroid therapy[16].
- **Patient Education:** Patients should be informed about the signs and symptoms of common irAEs. Educating patients on the importance of early reporting can lead to timely intervention and prevent the progression of irAEs.

General Management Strategies

Corticosteroids: Corticosteroids are the cornerstone of treatment for most moderate to severe irAEs. They reduce inflammation and suppress the immune response. The dosage and duration of corticosteroid therapy are determined based on the severity of the irAE.

- **Mild irAEs:** Managed with supportive care and, if necessary, low-dose corticosteroids.
- **Moderate irAEs:** Often require higher doses of corticosteroids (e.g., prednisone 0.5-1 mg/kg/day).
- **Severe irAEs:** May necessitate high-dose corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day), and hospitalization might be required for intensive monitoring and treatment.

Immunosuppressive Agents: In cases where corticosteroids are ineffective or not well-tolerated, additional immunosuppressive agents such as infliximab, mycophenolate mofetil, or tacrolimus may be used. The choice of agent depends on the specific irAE and the patient's overall health status

Future Directions

The field of ICIs is rapidly evolving, with ongoing research focusing on optimizing treatment outcomes and mitigating adverse effects. Key future directions include refining patient selection criteria, improving management of side effects, identifying predictive biomarkers, and advancing computational algorithms and personalized medicine.

Conclusion

The emergence of immune checkpoint inhibitors (ICIs) has revolutionized the management of various cancers, offering new hope through enhanced survival rates and durable responses. Pembrolizumab, a prominent PD-1 inhibitor, exemplifies this transformation with its proven efficacy across multiple malignancies, including non-small cell lung cancer, melanoma, and gastric cancer. Its ability to restore immune surveillance by blocking the PD-1/PD-L1 interaction underscores a pivotal shift from traditional cytotoxic therapies to immunotherapy, leveraging the body's immune system to target and destroy cancer cells.

Despite their significant benefits, ICIs are not without challenges. Pembrolizumab, like other ICIs, is associated with a range of immune-related adverse events (irAEs), such as dermatologic, gastrointestinal, and hematologic issues. While these side effects are generally manageable, their early detection and prompt management are critical to optimizing patient outcomes. The use of corticosteroids remains the cornerstone of treatment for severe irAEs, but the development of more targeted and personalized management strategies is essential.

Looking forward, the field of ICI therapy is poised for substantial advancements. Enhancing patient selection through refined biomarkers, such as tumor mutational burden and microsatellite instability, will likely improve treatment precision and efficacy. Additionally, ongoing research into predictive biomarkers, including circulating tumor DNA and immune cell profiling, holds promise for more accurately forecasting patient responses and adverse effects.

The integration of advanced computational algorithms and personalized medicine approaches represents another exciting frontier. By harnessing machine learning and genomic data, future strategies aim to tailor treatments more precisely, predict responses, and mitigate resistance. Furthermore, novel approaches such as fecal microbiota transplantation offer intriguing possibilities for enhancing ICI efficacy and managing irAEs, potentially paving the way for more effective and personalized cancer therapies.

In summary, while Pembrolizumab and other ICIs have ushered in a new era of cancer treatment, continued research and innovation are crucial to overcoming current limitations and fully realizing their potential. The future of ICI therapy will depend on our ability to refine patient selection, manage adverse effects effectively, and leverage cutting-edge technologies to deliver personalized and optimized care.

References

1. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Human Vaccines Immunotherapeutics 2016;12(11):2777-2789.
2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Eng J Medicine 2016;375(19):1823-1833.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med 2015;373(23):23-34.
4. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Lancet Oncol 2012;16(4):435-445.
5. Hanna K, Ruttan T, Makarov V, Patil S. Pembrolizumab in advanced melanoma: Real-world experience. J Clin Oncol 2017;35:e19107-e19107.
6. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2

randomised controlled trial. Lancet 2017;389(10066):255-265.

7. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14(4):847-856.
8. Sacher AG, Gandara DR, Felip E. Tumor mutation burden and response to immune checkpoint inhibitors. J Clinical Oncol 2016;34:e17552-e17552.
9. Gopalakrishnan V, Spencer CN, Nezi L, Helmink BA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359(6371):97-103.
10. Johnson DB, Sullivan RJ, Makhoul I. Immune checkpoint inhibitors in the treatment of melanoma: Safety and efficacy. J Clin Oncol 2016;34: e18153-e18153.
11. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Eng J Med 2015;373(19).
12. Wang L, Shi Y. Autoimmune hemolytic anemia induced by Pembrolizumab. J Hematol Oncol 2020;13(1):8.
13. Valpione S, Kotecha R. Immune-related thrombocytopenia with Pembrolizumab. Cancer Immunol Immunoth 2020;69(10):1927-1935.
14. Marabelle A, Le DT, Ascierto PA. Efficacy of Pembrolizumab in patients with microsatellite instability-high colorectal cancer: Updated results from the KEYNOTE-164 trial. J Clin Oncol 2020;38:4508.
15. Atkinson R, Shaw JW, Alarcon T. Management of anemia and neutropenia in cancer patients receiving Pembrolizumab. Oncol Nursing Forum 2019;46(2):127-135.
16. Haanen JB, Carbonnel F. Management of adverse events following treatment with anti-PD-1/PD-L1 therapy. Ann Oncol 2018;29.
17. Rizvi NA, Hellmann MD. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-128.
18. Yang Y, Xu J. Advances in imaging technologies for predicting and monitoring immune checkpoint inhibitor therapy. Current Oncology Rep 2020;22(11):106.
19. Dougan M, Shulman H. Management of immune-related adverse events from immune checkpoint inhibitors. Current Opinion Oncol 2020;32(5):632-638.
20. Wang H, Zhang H. Predictive biomarkers for immune checkpoint inhibitor therapy: A systematic review and meta-analysis. Front Oncol 2021;11:736738.
21. Cortellini A, Bersanelli M. Management of immune-related adverse events from immune checkpoint inhibitors: A review of current guidelines. Expert Rev Anticancer Ther 2019;19(9):761-774.
22. Cohen JV, Chung CH. Circulating tumor DNA and immune checkpoint inhibitors: A promising combination for precision oncology. Clinical Cancer Res 2021;27(7):1780-1788.
23. Sato T, Hoshida Y. Advances in immune cell profiling for predictive biomarkers of immune checkpoint inhibitor therapy. Immuno-Oncology Technol 2022;9:100074.
24. Lee MJ, Lee H. Machine learning algorithms for predicting immune checkpoint inhibitor responses. Cancer Immunol Res 2021;9(8):848-859.
25. Saad A, Moin D. Personalized medicine in immune checkpoint inhibitor therapy: Current progress and future directions. Molecular Med 2022;28(1):64.
26. Yaguchi T, Nishio M. Advances in combination therapies involving immune checkpoint inhibitors. Front Oncol 2021;11:644406.
27. Mazzoni A, D'Alessio S. Fecal microbiota transplantation in cancer immunotherapy: A new approach to enhance efficacy and mitigate adverse effects. Gastroenterology Res Practice 2020.
28. Gopalakrishnan V, Spencer CN. The impact of fecal microbiota transplantation on immune checkpoint inhibitors: Evidence and future perspectives. J Immunother 2021;44(2):46-54.